TherapeuticsMD Inc (NASDAQ:TXMD) Director Brian Bernick sold 182,800 shares of TherapeuticsMD stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $5.07, for a total transaction of $926,796.00. Following the transaction, the director now directly owns 242,000 shares of the company’s stock, valued at approximately $1,226,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Brian Bernick also recently made the following trade(s):

  • On Friday, November 30th, Brian Bernick sold 91,400 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.96, for a total transaction of $453,344.00.
  • On Tuesday, November 20th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.74, for a total transaction of $866,472.00.
  • On Friday, November 9th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $4.88, for a total transaction of $892,064.00.
  • On Friday, October 19th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.56, for a total transaction of $1,016,368.00.
  • On Friday, October 5th, Brian Bernick sold 91,400 shares of TherapeuticsMD stock. The stock was sold at an average price of $5.93, for a total transaction of $542,002.00.
  • On Friday, September 28th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $6.59, for a total transaction of $1,204,652.00.
  • On Thursday, September 13th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The stock was sold at an average price of $6.30, for a total transaction of $1,151,640.00.

NASDAQ:TXMD opened at $4.63 on Friday. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.51 and a beta of 1.35. TherapeuticsMD Inc has a 12 month low of $4.30 and a 12 month high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Wednesday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The business’s revenue was down 21.5% on a year-over-year basis. During the same period last year, the company earned ($0.07) earnings per share. As a group, research analysts anticipate that TherapeuticsMD Inc will post -0.58 EPS for the current year.

TXMD has been the subject of a number of research reports. Oppenheimer set a $14.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, August 13th. Cantor Fitzgerald set a $26.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Friday, August 10th. JPMorgan Chase & Co. set a $11.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, August 15th. ValuEngine upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 21st. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Wednesday, October 17th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. TherapeuticsMD has an average rating of “Buy” and an average target price of $13.45.

Several hedge funds and other institutional investors have recently modified their holdings of TXMD. FMR LLC grew its holdings in shares of TherapeuticsMD by 14.7% during the third quarter. FMR LLC now owns 12,049,988 shares of the company’s stock valued at $79,048,000 after buying an additional 1,542,987 shares during the last quarter. BlackRock Inc. grew its holdings in shares of TherapeuticsMD by 10.6% during the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock valued at $105,421,000 after buying an additional 1,537,045 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of TherapeuticsMD during the third quarter valued at about $9,840,000. Nexthera Capital LP acquired a new position in shares of TherapeuticsMD during the third quarter valued at about $8,575,000. Finally, Vanguard Group Inc. grew its holdings in shares of TherapeuticsMD by 9.8% during the third quarter. Vanguard Group Inc. now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after buying an additional 1,153,716 shares during the last quarter. Hedge funds and other institutional investors own 72.66% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “TherapeuticsMD Inc (TXMD) Director Brian Bernick Sells 182,800 Shares” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-director-brian-bernick-sells-182800-shares/2666670.html.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Further Reading: Terms to Better Understand Call Options

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.